JACC:缺血性心肌病:基质消融优于稳定VTs消融

2015-12-23 cuiqian译 MedSci原创

导管消融减少缺血性心肌病和室性心动过速(VT)患者的VT复发和植入式心律转复除颤电击。最有效的导管消融技术是未知的。这项研究旨在确定在接受消融仅限于临床VT伴随可制图的VTs(“临床消融术”) vs 基质的消融患者的VT复发率。缺血性心肌病和血流动力学稳定的VT受试者被随机分配到接受临床消融(n=60) vs 针对疤痕“异常”电图(n=58)的基质消融。主要终点是复发的VT。次要终点包括围手术期并

导管消融可减少缺血性心肌病和室性心动过速(VT)患者的VT复发和植入式心律转复除颤电击。但最有效的导管消融技术是未知的。

这项研究旨在确定在接受消融仅限于临床VT伴随可制图的VTs(“临床消融术”) vs 基质的消融患者的VT复发率。

缺血性心肌病和血流动力学稳定的VT受试者被随机分配到接受临床消融(n=60) vs 针对疤痕“异常”电图(n=58)的基质消融。主要终点是复发的VT。次要终点包括围手术期并发症,12个月的死亡率和再次住院。

在12个月的随访过程中,基质和临床VT消融组分别有9例(15.5%)和29例(48.3%)患者有VT复发(数秩P<0.001)。接受临床VT消融的患者在消融术后服用抗心律失常药物的患者(58%)比基质消融的患者多(12%,P<0.001)。基质消融的7例患者(12%)和临床VT的19例患者(32%)需要再住院(p=0.014)。总体12个月病死率为11.9%;基质消融组和临床消融组分别为8.6%和15.0%(对数秩p=0.21)。基质消融组的再住院和死亡的组合发生率显著降低(p=0.003)。围手术期并发症两组相似(P=0.61)。

对于缺血性心肌病呈现出VT耐受性的患者,一个广泛的基质消融方法是优于只针对临床和稳定的VTs消融方法的。

原始出处:

Luigi Di Biase, David Burkhardt,Dhanujaya Lakkireddy,et al.Ablation of Stable VTs Versus Substrate Ablation in Ischemic Cardiomyopathy,JACC,2015.12.22

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (18)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1757036, encodeId=17761e570368d, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Thu Jun 23 23:10:00 CST 2016, time=2016-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853457, encodeId=e574185345e59, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu May 05 03:10:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892710, encodeId=fd981892e10ac, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Nov 04 12:10:00 CST 2016, time=2016-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59990, encodeId=7ed6599901f, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:23:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59991, encodeId=ca2a59991cb, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:23:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55087, encodeId=2b9d5508e86, content=不错不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 21:56:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55088, encodeId=e13c5508816, content=不错不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 21:56:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55089, encodeId=436655089e5, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 21:56:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55090, encodeId=f3915509048, content=谢谢分享,, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 21:56:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55086, encodeId=a2265508605, content=不错不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 21:56:00 CST 2016, time=2016-01-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1757036, encodeId=17761e570368d, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Thu Jun 23 23:10:00 CST 2016, time=2016-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853457, encodeId=e574185345e59, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu May 05 03:10:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892710, encodeId=fd981892e10ac, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Nov 04 12:10:00 CST 2016, time=2016-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59990, encodeId=7ed6599901f, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:23:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59991, encodeId=ca2a59991cb, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:23:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55087, encodeId=2b9d5508e86, content=不错不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 21:56:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55088, encodeId=e13c5508816, content=不错不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 21:56:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55089, encodeId=436655089e5, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 21:56:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55090, encodeId=f3915509048, content=谢谢分享,, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 21:56:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55086, encodeId=a2265508605, content=不错不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 21:56:00 CST 2016, time=2016-01-09, status=1, ipAttribution=)]
    2016-05-05 hbwxf
  3. [GetPortalCommentsPageByObjectIdResponse(id=1757036, encodeId=17761e570368d, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Thu Jun 23 23:10:00 CST 2016, time=2016-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853457, encodeId=e574185345e59, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu May 05 03:10:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892710, encodeId=fd981892e10ac, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Nov 04 12:10:00 CST 2016, time=2016-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59990, encodeId=7ed6599901f, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:23:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59991, encodeId=ca2a59991cb, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:23:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55087, encodeId=2b9d5508e86, content=不错不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 21:56:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55088, encodeId=e13c5508816, content=不错不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 21:56:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55089, encodeId=436655089e5, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 21:56:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55090, encodeId=f3915509048, content=谢谢分享,, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 21:56:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55086, encodeId=a2265508605, content=不错不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 21:56:00 CST 2016, time=2016-01-09, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1757036, encodeId=17761e570368d, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Thu Jun 23 23:10:00 CST 2016, time=2016-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853457, encodeId=e574185345e59, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu May 05 03:10:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892710, encodeId=fd981892e10ac, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Nov 04 12:10:00 CST 2016, time=2016-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59990, encodeId=7ed6599901f, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:23:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59991, encodeId=ca2a59991cb, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:23:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55087, encodeId=2b9d5508e86, content=不错不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 21:56:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55088, encodeId=e13c5508816, content=不错不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 21:56:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55089, encodeId=436655089e5, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 21:56:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55090, encodeId=f3915509048, content=谢谢分享,, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 21:56:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55086, encodeId=a2265508605, content=不错不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 21:56:00 CST 2016, time=2016-01-09, status=1, ipAttribution=)]
    2016-01-26 doctording1

    这篇文章有一定深度

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1757036, encodeId=17761e570368d, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Thu Jun 23 23:10:00 CST 2016, time=2016-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853457, encodeId=e574185345e59, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu May 05 03:10:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892710, encodeId=fd981892e10ac, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Nov 04 12:10:00 CST 2016, time=2016-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59990, encodeId=7ed6599901f, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:23:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59991, encodeId=ca2a59991cb, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:23:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55087, encodeId=2b9d5508e86, content=不错不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 21:56:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55088, encodeId=e13c5508816, content=不错不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 21:56:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55089, encodeId=436655089e5, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 21:56:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55090, encodeId=f3915509048, content=谢谢分享,, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 21:56:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55086, encodeId=a2265508605, content=不错不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 21:56:00 CST 2016, time=2016-01-09, status=1, ipAttribution=)]
    2016-01-26 doctording1

    是一篇不错的文章

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1757036, encodeId=17761e570368d, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Thu Jun 23 23:10:00 CST 2016, time=2016-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853457, encodeId=e574185345e59, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu May 05 03:10:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892710, encodeId=fd981892e10ac, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Nov 04 12:10:00 CST 2016, time=2016-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59990, encodeId=7ed6599901f, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:23:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59991, encodeId=ca2a59991cb, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:23:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55087, encodeId=2b9d5508e86, content=不错不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 21:56:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55088, encodeId=e13c5508816, content=不错不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 21:56:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55089, encodeId=436655089e5, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 21:56:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55090, encodeId=f3915509048, content=谢谢分享,, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 21:56:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55086, encodeId=a2265508605, content=不错不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 21:56:00 CST 2016, time=2016-01-09, status=1, ipAttribution=)]
    2016-01-09 medsic

    不错不错,

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1757036, encodeId=17761e570368d, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Thu Jun 23 23:10:00 CST 2016, time=2016-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853457, encodeId=e574185345e59, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu May 05 03:10:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892710, encodeId=fd981892e10ac, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Nov 04 12:10:00 CST 2016, time=2016-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59990, encodeId=7ed6599901f, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:23:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59991, encodeId=ca2a59991cb, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:23:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55087, encodeId=2b9d5508e86, content=不错不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 21:56:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55088, encodeId=e13c5508816, content=不错不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 21:56:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55089, encodeId=436655089e5, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 21:56:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55090, encodeId=f3915509048, content=谢谢分享,, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 21:56:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55086, encodeId=a2265508605, content=不错不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 21:56:00 CST 2016, time=2016-01-09, status=1, ipAttribution=)]
    2016-01-09 medsic

    不错不错,

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1757036, encodeId=17761e570368d, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Thu Jun 23 23:10:00 CST 2016, time=2016-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853457, encodeId=e574185345e59, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu May 05 03:10:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892710, encodeId=fd981892e10ac, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Nov 04 12:10:00 CST 2016, time=2016-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59990, encodeId=7ed6599901f, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:23:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59991, encodeId=ca2a59991cb, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:23:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55087, encodeId=2b9d5508e86, content=不错不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 21:56:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55088, encodeId=e13c5508816, content=不错不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 21:56:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55089, encodeId=436655089e5, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 21:56:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55090, encodeId=f3915509048, content=谢谢分享,, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 21:56:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55086, encodeId=a2265508605, content=不错不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 21:56:00 CST 2016, time=2016-01-09, status=1, ipAttribution=)]
    2016-01-09 medsic

    好文章

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1757036, encodeId=17761e570368d, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Thu Jun 23 23:10:00 CST 2016, time=2016-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853457, encodeId=e574185345e59, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu May 05 03:10:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892710, encodeId=fd981892e10ac, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Nov 04 12:10:00 CST 2016, time=2016-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59990, encodeId=7ed6599901f, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:23:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59991, encodeId=ca2a59991cb, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:23:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55087, encodeId=2b9d5508e86, content=不错不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 21:56:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55088, encodeId=e13c5508816, content=不错不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 21:56:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55089, encodeId=436655089e5, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 21:56:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55090, encodeId=f3915509048, content=谢谢分享,, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 21:56:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55086, encodeId=a2265508605, content=不错不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 21:56:00 CST 2016, time=2016-01-09, status=1, ipAttribution=)]
    2016-01-09 medsic

    谢谢分享,

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1757036, encodeId=17761e570368d, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Thu Jun 23 23:10:00 CST 2016, time=2016-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853457, encodeId=e574185345e59, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu May 05 03:10:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892710, encodeId=fd981892e10ac, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Nov 04 12:10:00 CST 2016, time=2016-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59990, encodeId=7ed6599901f, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:23:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59991, encodeId=ca2a59991cb, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:23:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55087, encodeId=2b9d5508e86, content=不错不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 21:56:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55088, encodeId=e13c5508816, content=不错不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 21:56:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55089, encodeId=436655089e5, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 21:56:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55090, encodeId=f3915509048, content=谢谢分享,, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 21:56:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55086, encodeId=a2265508605, content=不错不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 21:56:00 CST 2016, time=2016-01-09, status=1, ipAttribution=)]
    2016-01-09 medsic

    不错不错,

    0

相关资讯

J Thorac Cardiovasc Surg:左心室辅助装置 VS常规手术

  严重的缺血性心肌病(左心室射血分数<25%)和重度缺血性二尖瓣关闭不全的患者单纯药物治疗预后较差。常规意义上,作为目标治疗的左心室辅助装置通常用于常规手术风险太高的患者。近期,发表于The Journal of Thoracic and Cardiovascular Surgery上一篇文章的评估了对于这类患者传统的手术和这个疗

磁共振对预测缺血性心肌病患者并发心源性猝死的原理和应用价值

摘要:心肌瘢痕及瘢痕边缘区是缺血性心肌病患者产生心肌电不稳定并发心源性猝死的病理基质。通过心血管磁共振测定缺血性心肌病患者的心肌瘢痕及瘢痕边缘区的大小和比例,有助于此类患者并发心源性猝死的危险分层和预测。 冠心病是心源性猝死(sudden cardiac death, SCD)最常见的病因,所占比率可达80% [1] 。由冠心病导致心肌瘢痕形成的缺血性心肌病患者,SCD发生率明显升高 [2

干细胞治疗缺血性心肌病取得新进展

 美国学者研究发现,经导管心肌内注射自体骨髓祖细胞可改善慢性瘢痕心肌的局部收缩力,逆转心脏重构,提示这种新的治疗策略以及与之相关的、正在进行中的随机临床试验具有潜在的临床价值。该研究3月17日在线发表于《循环研究》(Circ Res)杂志。   8例(平均年龄57.2岁)患者接受了心内膜、心肌注射自体骨髓祖细胞至左心室梗死后瘢痕及其边缘的治疗,过程中未出现严重不良事件。1年内心脏核磁共

JAMA:对缺血性心肌病患者使用干细胞及骨髓细胞疗法是安全的

芝加哥 – 迈阿密大学米勒医学院的Alan W. Heldman, M.D.及其同事开展了一项研究,旨在检查在罹患缺血性心肌病的病人中所做的经心内膜干细胞注射(TESI)自体间充质干细胞和骨髓单核细胞的安全性。 对缺血性心肌病的一种有效的促再生疗法将能解决许多病人的一个主要的未得到满足的需要。根据文章的背景资料,一个悬而未决的问题是,间充质干细胞是否有着类似的安全性及可能比骨髓单核细胞更大的功效

AHA2012年会:心肌干细胞输注促进梗死心肌再生

     在11月6日的美国心脏学会(AHA)2012科学年会上,美国一项有关干细胞输注治疗缺血性心肌病的试验(SCIPIO)引人注目,该试验研究了心肌干细胞(CSCs)而不是骨髓干细胞对心力衰竭患者的益处,而且初步结果令人振奋。   SCIPIO是一个随机开放标签的1期临床试验,研究对象为心肌梗死后左室射血分数(LVEF)<40%的心衰患者,使用c-KIT-阳性CSCs。细胞来源于患者

JAMA:经心肌注射自体间充质干细胞或骨髓单个核细胞治疗缺血性心肌病是安全的(TAC-HFT试验)

    最近基础研究和临床试验表明骨髓来源细胞提取成分,包括单个核骨髓细胞和间充质干细胞可以减轻急性心梗和慢性缺血性心肌病左室重塑。针对缺血性心肌病有效的抑制重塑、促进再生的治疗将会解决许多病人的主要问题。通过培养扩增的骨髓中的间充质干细胞,由于更强的分化能力,推测其可能可以形成异位组织或刺激肿瘤形成,但也拥有比骨髓单个核细胞更强的抗纤维化以及促进再生的能力。间充